Website: N/A
Stock Symbol: NASDAQ: XOMA
Market Value: N/A (in millions)
XOMA Ltd. (“XOMA” or the “Company”), a Bermuda company, is a leading
biopharmaceutical company focused on the discovery, development and manufacture
of therapeutic antibodies. XOMA uses its expertise, technologies and
capabilities to build a product pipeline that includes multiple proprietary and
collaborative development programs. The Company’s lead product candidate is XOMA
052, a high affinity anti-IL-1 beta antibody with the potential to treat
multiple inflammatory diseases of large unmet need. XOMA 052 is currently in
Phase 1 clinical studies of Type 2 diabetes patients.
XOMA has multiple revenue streams and generates revenues from product royalties,
technology licenses, development collaborations and biodefense contracts.